Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Drugmaker to Test Machine Learning to Prevent Drug Shortageson October 14, 2019 at 12:09 pm
Common classes of drugs in short supply include antibiotics, chemotherapy and cardiovascular treatments. Analysts say more precise supply-and-demand forecasts mean pharmaceutical companies could save ...
- NIH Grant Aims to Reduce Effects of Chemotherapyon October 14, 2019 at 10:49 am
and impaired gait and balance related to receiving the common class of cancer drugs called taxanes. “If successful, it will provide the only evidence-based intervention for patients suffering from ...
- Platinum Based Cancer Drugs Market Size Is Projected To Reach USD 1,814.1 Million by 2026 | Polaris Market Researchon October 14, 2019 at 9:08 am
Drugs based on platinum have become a major component of cancer therapy; about half of all patients undergoing chemotherapy receive a platinum drug. The widespread use of platinum agents in cancer ...
- Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study findson October 14, 2019 at 7:03 am
The new finding, recently published in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are ...
- Oncology/Cancer Drugs Market to Reach $176.50 Bn, Globally, by 2025 at 7.6% CAGR: Allied Market Researchon October 14, 2019 at 7:00 am
PORTLAND, Oregon, Oct. 14, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and ...
- Woman rings chemotherapy bell after fighting breast cancer while pregnanton October 13, 2019 at 8:11 pm
Newer research has shown certain chemotherapy drugs used during the second and third trimesters are safe, but researchers "still don’t know if these children will have any long-term effects," ...
- In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cellson October 13, 2019 at 3:51 pm
We established gastric cancer patient-derived cells (PDCs) to examine the contribution of CD44 splicing variant 9 (CD44v9)-positive cells in gastric cancer drug tolerance. We performed gene expression ...
- Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fundon October 11, 2019 at 5:05 pm
“For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited ... is essential in the fight against this deadly disease and central to Clovis Oncology’s mission to ...
- Amgen's Latest Data With KRAS G12C Inhibitor Drug Is Mixed, But Can Still Shine On Prior Evidenceon October 10, 2019 at 9:12 am
However, I believe that Amgen can eventually do well as it explores its other options. Such options are combining AMG 510 with other anti-cancer drugs to improve clinical outcomes. Results that were ...
via Bing News